Concord Wealth Partners’s Q32 Bio QTTB Stock Holding History

Concord Wealth Partners’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-14	Closed	-$2K	–	1356
2021 Q3	$2K	Buy	+14	New	+$1.78K	﹤0.01%	789

Other funds holding QTTB

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Concord Wealth Partners's QTTB Position: Q4 2021 in Review

Concord Wealth Partners sold out of Q32 Bio (QTTB) in Q4 2021, closing a stake of 14 shares — an estimated $2K sold.

Concord Wealth Partners first reported a position in QTTB in Q3 2021 and held it in 1 quarter. The position peaked at $2K in Q3 2021. 120 funds tracked by Wall St. Rank hold QTTB as of Q4 2021.

Concord Wealth Partners reported no remaining Q32 Bio position as of Q4 2021 after selling out during the quarter.
Concord Wealth Partners sold 14 Q32 Bio shares in Q4 2021, an estimated $2K.
Concord Wealth Partners first reported a position in Q32 Bio in Q3 2021 and held it in 1 quarter.
Concord Wealth Partners's Q32 Bio position peaked at $2K in Q3 2021.
120 funds tracked by Wall St. Rank held Q32 Bio as of Q4 2021.

Based on Concord Wealth Partners's 13F filing for Q4 2021, filed 21 Jan 2022.